INTRODUCTION: Weight gain is a common and severe side effect of antipsychotic drugs. A usual tool to study the side effects of psychotropic drugs is animal models. However, attempts to create an animal model of antipsychotic-induced weight gain were not successful so far. Female rodents are sensitive to the effects of antipsychotics, but not males. This does not match the human clinical situation. Antipsychotics have different pharmacokinetic properties in rats and humans, and rats and humans have different spontaneous diets. MATERIALS AND METHODS: In the present study, we tested the hypothesis that the insensitivity of male rats to the weight-promoting effects of antipsychotics could be related to the mode of administration of antipsychotics and to the animals' diet. Antipsychotics were mixed with the food, and rats were fed a diet resembling the human diet. Rats were treated with 0.01, 0.1, 0.5, and 2 mg/kg of olanzapine or with a control solution for 6 weeks. Their weight and food intake were recorded, and their body composition were analyzed. The effects on weight and food intake of olanzapine (1 mg/kg), haloperidol (1 mg/kg), and ziprasidone (10 mg/kg) were also compared in a 3-week treatment experiment. RESULTS: The results showed that 0.5 and 2 mg of olanzapine, but not lower doses, increase body weight and subcutaneous fat deposition. After the 3-week treatment, olanzapine-treated rats, but not haloperidol- or ziprasidone-treated rats, had significantly increased their weight. CONCLUSION: This study shows that a rat model of obesity induced by antipsychotics can be created under specific conditions of drug administration, diet, and dose.
INTRODUCTION:Weight gain is a common and severe side effect of antipsychotic drugs. A usual tool to study the side effects of psychotropic drugs is animal models. However, attempts to create an animal model of antipsychotic-induced weight gain were not successful so far. Female rodents are sensitive to the effects of antipsychotics, but not males. This does not match the human clinical situation. Antipsychotics have different pharmacokinetic properties in rats and humans, and rats and humans have different spontaneous diets. MATERIALS AND METHODS: In the present study, we tested the hypothesis that the insensitivity of male rats to the weight-promoting effects of antipsychotics could be related to the mode of administration of antipsychotics and to the animals' diet. Antipsychotics were mixed with the food, and rats were fed a diet resembling the human diet. Rats were treated with 0.01, 0.1, 0.5, and 2 mg/kg of olanzapine or with a control solution for 6 weeks. Their weight and food intake were recorded, and their body composition were analyzed. The effects on weight and food intake of olanzapine (1 mg/kg), haloperidol (1 mg/kg), and ziprasidone (10 mg/kg) were also compared in a 3-week treatment experiment. RESULTS: The results showed that 0.5 and 2 mg of olanzapine, but not lower doses, increase body weight and subcutaneous fat deposition. After the 3-week treatment, olanzapine-treated rats, but not haloperidol- or ziprasidone-treated rats, had significantly increased their weight. CONCLUSION: This study shows that a rat model of obesity induced by antipsychotics can be created under specific conditions of drug administration, diet, and dose.
Authors: Valérie Rolland; Suzanne Roseau; Gilles Fromentin; Stylianos Nicolaidis; Daniel Tomé; Patrick C Even Journal: Am J Clin Nutr Date: 2002-01 Impact factor: 7.045
Authors: Donna A Wirshing; Jennifer A Boyd; Laura R Meng; Jacob S Ballon; Stephen R Marder; William C Wirshing Journal: J Clin Psychiatry Date: 2002-10 Impact factor: 4.384
Authors: Julie Minet-Ringuet; Patrick C Even; Benjamin Guesdon; Daniel Tomé; Renaud de Beaurepaire Journal: Behav Brain Res Date: 2005-09-08 Impact factor: 3.332
Authors: Trino Baptista; Emma Araujo de Baptista; Josee Lalonde; Julie Plamondon; N M K Ng Ying Kin; Serge Beaulieu; Rhida Joober; Denis Richard Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2004-12 Impact factor: 5.067
Authors: Heidi N Boyda; Ric M Procyshyn; Lurdes Tse; Erin Hawkes; Chen H Jin; Catherine C Y Pang; William G Honer; Alasdair M Barr Journal: J Psychiatry Neurosci Date: 2012-11 Impact factor: 6.186
Authors: Martina von Wilmsdorff; Fabian Manthey; Marie-Luise Bouvier; Oliver Staehlin; Peter Falkai; Eva Meisenzahl-Lechner; Andrea Schmitt; Peter J Gebicke-Haerter Journal: Eur Arch Psychiatry Clin Neurosci Date: 2018-02-05 Impact factor: 5.270
Authors: Emily J McAllister; Nikhil V Dhurandhar; Scott W Keith; Louis J Aronne; Jamie Barger; Monica Baskin; Ruth M Benca; Joseph Biggio; Mary M Boggiano; Joe C Eisenmann; Mai Elobeid; Kevin R Fontaine; Peter Gluckman; Erin C Hanlon; Peter Katzmarzyk; Angelo Pietrobelli; David T Redden; Douglas M Ruden; Chenxi Wang; Robert A Waterland; Suzanne M Wright; David B Allison Journal: Crit Rev Food Sci Nutr Date: 2009-11 Impact factor: 11.176
Authors: Johan Fernø; Audun O Vik-Mo; Goran Jassim; Bjarte Håvik; Kjetil Berge; Silje Skrede; Oddrun A Gudbrandsen; Jo Waage; Niclas Lunder; Sverre Mørk; Rolf K Berge; Hugo A Jørgensen; Vidar M Steen Journal: Psychopharmacology (Berl) Date: 2008-10-30 Impact factor: 4.530
Authors: Hiren R Modi; Ameer Y Taha; Hyung-Wook Kim; Lisa Chang; Stanley I Rapoport; Yewon Cheon Journal: J Neurochem Date: 2012-12-06 Impact factor: 5.372
Authors: Louise Benarroch; Chantel Kowalchuk; Virginia Wilson; Celine Teo; Melanie Guenette; Araba Chintoh; Yasika Nesarajah; Valerie Taylor; Peter Selby; Paul Fletcher; Gary J Remington; Margaret K Hahn Journal: Psychopharmacology (Berl) Date: 2016-06-01 Impact factor: 4.530